Emergent BioSolutions filings document an operating public-health company with NYSE-listed common stock under the symbol EBS. Its Form 8-K reports cover financial results, investor presentations, Regulation FD materials, debt prepayments, credit agreements, and other capital-structure events tied to its term loan and asset-based revolving facility.
Proxy and annual-meeting filings describe board elections, director appointments, committee service, auditor ratification, executive compensation, equity awards, and stockholder voting results. The filing record also captures governance disclosures for a company supplying NARCAN® Nasal Spray, ACAM2000®, and other medical countermeasure and bioservices products.
Emergent BioSolutions Inc. (EBS) announced a finance leadership transition: Richard Lindahl will step down as chief financial officer and principal financial and accounting officer effective December 31, 2026, and serve as an advisor through March 31, 2027, when he is scheduled to retire. Frank Vargo, the company’s vice president and treasurer, will become interim chief financial officer and principal financial and accounting officer on January 1, 2027.
The board approved additional interim compensation of $3,850 per pay period for Vargo beginning January 1, 2027, in addition to his current base salary of $328,000. His salary, bonus and equity awards will remain commensurate with his seniority and position before the appointment and will be reviewed on the same cycle as those of other executive officers. Lindahl will assist with the transition, including preparing and filing the Annual Report on Form 10-K for the year ending December 31, 2026.
Emergent BioSolutions Inc. director Donald DeGolyer reported a proposed sale of 17,800 shares of common stock, with an aggregate market value of $126,120.12 and an approximate sale date of October 7, 2026. The notice names Morgan Stanley Smith Barney LLC as broker and lists the securities exchange as NYSE.
Emergent BioSolutions Inc. director Donald W. DeGolyer sold 17,800 shares of common stock on October 7, 2026, at a weighted average price of $7.09 per share. The sale was made under a Rule 10b5-1 trading plan dated August 11, 2025, to satisfy tax obligations relating to RSUs scheduled to vest on October 2, 2026. DeGolyer directly held 111,921 shares after the sale.
Emergent BioSolutions Inc. reported that Paul Anthony Williams, SVP, Products Business, sold 3,000 shares of common stock on October 1, 2026, at a weighted average price of $6.53 per share; the individual sale prices ranged from $6.52 to $6.56. The sale was made under a Rule 10b5-1(c) trading plan adopted November 14, 2025. Williams directly held 156,098 shares after the sale.
Emergent BioSolutions Inc. officer Paul Williams, whose signature appears as Paul Anthony Williams, reported a proposed sale of 3,000 common shares, with an aggregate market value of $19,591.50 and an approximate sale date of October 1, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The notice states that the shares were acquired upon restricted-stock vesting during the period from February 29, 2024, through June 8, 2025.
Emergent BioSolutions Inc. (EBS) used an investor presentation at the H.C. Wainwright conference to outline a turnaround built on biodefense growth, restructuring and debt reduction, alongside lowered 2026 guidance. For Q2 2026, total revenues were $234.3 million, up from $140.9 million a year earlier, driven by medical countermeasures (MCM) revenue of $168 million, the highest Q2 MCM level since 2020. Adjusted EBITDA rose to $96.5 million from $33.1 million, while the company reported a GAAP net loss of $180.2 million, including a $191.3 million impairment.
The company detailed a restructuring expected to generate about $40 million in annualized savings through workforce reductions, facility closures and asset sales, and highlighted a new growth organization and R&D investments such as a $50.4 million milestone payment for Ebanga®. Debt management actions include an April 2026 term-loan refinancing and repurchase of $75 million principal of unsecured bonds, leaving gross debt at $589.7 million and net debt at $450.0 million as of June 30, 2026. Full-year 2026 guidance was revised to total revenues of $645–$675 million (from $720–$760 million), a net loss of $(245)–$(225) million and adjusted EBITDA of $130–$150 million, with Q3 revenue expected at $110–$130 million.
Emergent BioSolutions Inc. (EBS) reported a new contract modification from the U.S. government to supply its anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted). On August 18, 2026, the company received Modification No. 21 under its long-standing BARDA AV7909 contract, authorizing procurement of additional CYFENDUS doses valued at approximately $24 million.
The BARDA AV7909 contract has been in place since September 30, 2016 and has been modified multiple times to support anthrax preparedness. The press release notes this award supports U.S. anthrax preparedness efforts and follows an earlier 2026 delivery order valued at up to $21.5 million to supply BioThrax® to the U.S. Department of War. CYFENDUS is FDA‑approved as a two‑dose anthrax vaccine for post‑exposure prophylaxis in adults 18–65 years of age when given with recommended antibacterial drugs.
American Century ETF Trust and affiliates reported passive ownership stakes in Emergent BioSolutions Inc. common stock on Schedule 13G. American Century ETF Trust reported beneficial ownership of 2,676,346 shares, representing 5.2% of the outstanding common stock, with sole voting and dispositive power over these shares.
American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research each reported beneficial ownership of 2,770,448 shares, or 5.4% of the class, all with sole voting and dispositive power and no shared power. The filing explains that various advisory clients of American Century Investment Management, including investment companies and institutional accounts, have rights to dividends and sale proceeds, but no single client holds more than 5% of the class.
Emergent BioSolutions Inc. reported the initial equity holdings of executive vice president and chief growth officer Stephanie Duatschek. She holds 197,416 shares of common stock, consisting of 55,639 shares and 141,777 unvested RSUs that generally vest in three equal annual installments. She also holds several employee stock options on common stock, with exercise prices ranging from $2.33 to $59.07 per share and expiration dates between 2028 and 2033. For options granted in 2021–2025, all or a portion of the underlying shares are already vested and exercisable as described in the footnotes.
Emergent BioSolutions Inc. reported Q2 2026 total revenues of $234.3 million, up from $140.9 million a year earlier, driven mainly by MCM Products revenue of $168.0 million versus $58.4 million, while Commercial Products revenue declined to $52.4 million from $67.5 million. First‑half 2026 revenues were $390.4 million versus $363.1 million in 2025.
The company recorded a non‑cash $191.3 million impairment of the NARCAN intangible asset, a $10.7 million loss on Gaithersburg assets held‑for‑sale and a $20.5 million loss on debt extinguishment, leading to a Q2 net loss of $180.2 million and basic/diluted EPS of $(3.49), compared with a $12.0 million loss in Q2 2025. For the first half, net loss was $173.4 million versus $56.0 million of income in 2025.
As of June 30 2026, total assets were $1.12 billion and stockholders’ equity had declined to $341.4 million from $522.6 million at year‑end 2025, reflecting the impairment and losses. Cash, cash equivalents and restricted cash were $140.9 million, operating cash flow was $22.3 million, and total debt remained $589.7 million, including $439.7 million of 3.875% Senior Unsecured Notes and a new $150.0 million term loan maturing in 2031.
During the half, Emergent paid a $50.4 million Ebanga‑related milestone, repurchased 1.9 million shares for $18.2 million under its reauthorized buyback program and reduced its warrant liability to $12.8 million from $21.7 million. Subsequent to quarter‑end, it approved an August 2026 restructuring plan eliminating about 114 positions and closing Gaithersburg wet labs, with expected charges of $10.0–$11.5 million and anticipated annualized savings of over $40.0 million.